RE:RE:RE:RE:Pfizer's Trillium & GBT M&A deals not the lastReposted from November:
Pfizer acquired preclinical Trillium Therapeutics in August 2021 for US$2.3 Billion, then Biohaven Pharmaceuticals in May 2022 for US$11.6 Billion and Global Blood Therapeutics in October 2022 for US$5.4 Billion (both of these last 2 deals being completed in October 2022) .... and now in Pfizer's Q3 earning report provided in November 2022 the company stated that the M&A activity recently seen will continue with new deals helping replace delining vaccine sales and lost revenue from patent expirations, as noted aove.
[This places ONCY in a favorable position given the established partnership already establshed with Pfizer and MercKGaA in the development of avelumab with ONCY's naturally occurring IV delivered OV pelareorep in the treatment of breast cancer]
Pfizer's "string of pearls" strategy includes "Bolt-on acquistions" and platform technologies as seen over the past 2 years, and ONCY's Immune Molecule Platform Technology in pelareorep and "bolt-on" appeal would suggest ONCY as a likely "pearl" of a company for another targeted acquisition by Pfizer.